| ¿µ¹® | adverse effect | ÇÑ±Û | ¿ªÈ¿°ú, À¯ÇØÈ¿°ú |
|---|---|---|---|
| ¼³¸í | ¾à¹°¿¡ ÀÇÇÑ Ä¡·á¸¦ ÇÒ ¶§ ³ªÅ¸³ª´Â Ä¡·á¸ñÀû¿¡ ºÎÇÕµÇÁö ¾Ê´Â ºÒÄèÇÑ ÀÛ¿ë, Áï ºÎÀÛ¿ëÀ» ¿ªÈ¿°ú·Î Ç¥ÇöÇÏ´Â °æ¿ì°¡ ÀÖ´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼´Â ¿ªÈ¿°ú¶õ ¡°¿¹¹æ, Áø´Ü, Ä¡·áÀÇ ¸ñÀûÀ¸·Î »ç¶÷¿¡°Ô »ó¿ë·®ÀÇ ¾àÀ» »ç¿ëÇÏ¿´À» ¶§ ¹ßÇöÇÏ´Â Àå¾Ö·Î, ÀǵµÇÏÁö ¾ÊÀº Àۿ롱À̶ó°í Á¤ÀÇÇϰí ÀÖ´Ù. ¾à¹°¿¡ ÀÇÇÑ Ä¡·á¸¦ ÇÒ ¶§, ƯÈ÷ ÁÖ¸ñÇÏ¿©¾ß ÇÒ ÀϹÝÀûÀÎ ¿ªÈ¿°ú·Î¼ ¾à¹°¾Ë·¹¸£±â, Á¶Ç÷Àå±â Àå¾Ö, °£-ÄáÆÏÀÇ Àå¾Ö, ¹°Áú ´ë»ç Àå¾Ö µîÀÌ ÀÖ´Ù. ÀÌ ¿Ü¿¡ ÀÓ»êºÎ¿¡°Ô Åõ¿©ÇÏ¿© ¹ß»ýÇÑ ±âÇü¹ß»ý, ¸¶¾à, °¢¼ºÁ¦, ±âŸ ÇâÁ¤½ÅÁ¦¿¡ ÀÇÇÑ ÀÇÁ¸¼º Çü¼ºµµ Áß¿äÇÏ´Ù. |
||
| ¿µ¹® | antihypertensive drug | ÇÑ±Û | °íÇ÷¾Ð¾à, Ç×°íÇ÷¾ÐÁ¦ |
|---|---|---|---|
| ¼³¸í | °íÇ÷¾ÐÀÇ Ä¡·á¿¡ »ç¿ëÇÏ¸ç ³ôÀº Ç÷¾ÐÀ» ³·Ãß´Â ¾à¹°À» ¸»ÇÑ´Ù. °íÇ÷¾Ð¾à¿¡´Â Ç÷°üÆòȰ±Ù¿¡ Á÷Á¢ ÀÛ¿ëÇÏ¿© À̿ϽÃŰ´Â Ç÷°üÈ®ÀåÁ¦(È÷µå¶ó¶óÁø), ±³°¨½Å°æÀÇ È°µ¿À» ¾îµð¼±°¡ Â÷´ÜÇÏ´Â ¾à¹°(·¹¼¼¸£ÇÉ, ¸ÞÆ¿µµÆÄ, ÇÁ·ÎÇÁ¶ó³ë·Ñ), ÀÌ´¢Á¦(ÇÁ·Î¼¼¹Ìµå, ¿¡Å¸Å©¸°»ê)ÀÌ »ç¿ëµÈ´Ù. |
||
| ¿µ¹® | antimalarial drug | ÇÑ±Û | ¸»¶ó¸®¾Æ¾à, Ç׸»¶ó¸®¾ÆÁ¦ |
|---|---|---|---|
| ¼³¸í | ¸»¶ó¸®¾Æ Ä¡·á¿¡ ¾²´Â ¾à. Ű´Ï³×, Ŭ·Î·ÎÄý, ÇÁ¸®¸¶Äý µûÀ§°¡ ÀÖ´Ù. ¸»¶ó¸®¾Æ ¿øÃæÀÇ ¹ßÀ°Áֱ⿡ ´ëÀÀÇØ¼ ¾à¹°ÀÌ ÀÖÀ¸³ª ´ëºÎºÐÀº º´¿ë¿ä¹ý¿¡ µû¶ó¼ ¸»¶ó¸®¾Æ Ä¡·á¸¦ ÇÑ´Ù. ¸ð±â¿¡ ÀÇÇÑ Æ÷ÀÚü°¨¿°¿¡ ´ëÇÑ Çׯ÷ÀÚü ¾àÀº µ¶¼º µîÀÇ ¹®Á¦°¡ ÀÖ¾î¼ ¾ÆÁ÷ ¾ø´Ù. ÀûÇ÷±¸³»¿¡¼ÀÇ È¯»óü, ¹ø½Äü¿¡¸¸ ÀÛ¿ëÇÏ´Â °Í(Ç×¹ø½Äü ¾àÀº Ŭ·Î·ÎÄý, ÇǸ®¸ÞŸ¹Î, Ŭ·Î·Î±¸¾Æ³ªÀ̵å, Ű´Ï³×)Àº ÀûÇ÷±¸ ¿ÜÀÇ ¹ßÀ°Àº ¾ïÁ¦ÇÏÁö ¾ÊÀ¸¹Ç·Î °¨¿°À» ¿ÏÀüÈ÷ ÀúÁöµÇÁö ¾Ê´Â´Ù. ÀûÇ÷±¸³»¿ÜÀÇ ¿øÃæ¿¡ ÀÛ¿ëÇØ ¿ÏÀüÈ÷ °¨¿°À» ¾ïÁ¦ÇÏ´Â °Í(ÆÄ¸¶Å², ÆæÅ¸Å², ÇÁ¸®¸¶Å²), Ç÷ÁßÀÇ »ý½Äü¸¦ Á×ÀÌ´Â °Í(´ëºÎºÐÀÇ Ç׸»¶ó¸®¾ÆÁ¦)Àº ¸ð±â¿¡ ÀÇÇÑ Å¸ÀÎÀ¸·ÎÀÇ Àü¿°¿øÀº ²÷±â´Âµ¥ ȯÀÚÀÚ½ÅÀÇ Áõ»óÀº º¯ÈÇÏÁö ¾Ê´Â´Ù. |
||
| ¿µ¹® | drug | ÇÑ±Û | ¾à, ¾à¹°, ¾àÁ¦ |
|---|---|---|---|
| ¼³¸í | 1. º´, ±âŸ º´Àû »óÅÂÀÇ Áø´Ü, Ä¡·á, ¿¹¹æÀ̳ª °íÅëÀÇ °æ°¨, ¶Ç´Â »ý¸®Àû, º´¸®Àû »óŸ¦ È£Àü½ÃŰ´Â °ÍÀ» ¸ñÀûÀ¸·Î »ç¶÷ ¶Ç´Â µ¿¹°¿¡ Åõ¿©µÇ´Â ÈÇÕ¹°. ¾à¸®Çп¡¼´Â Ä¡·á¾à¸¸ÀÌ ¾Æ´Ï¶ó, »ýü¿¡ ÁÖ¾îÁ³À» ¶§ ¾î¶°ÇÑ ¹ÝÀÀÀ» ³ªÅ¸³»´Â ÈÇй°Áú ¸ðµÎ¸¦ ¾à¹°À̶ó°í ÇÑ´Ù. ÀÛ¿ëÀÌ °ÇÏ°í ¾ÈÀü¼ºÀÌ ³·Àº ¼ø¼·Î µ¶¾à-±Ø¾à-º¸Åë¾àÀ¸·Î ±¸ºÐÇϰí ÀÖ´Ù. ¾à¹°Ä¡·á¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÎÀڷμ, »ýüÂÊ ÀÎÀڷδ °³Ã¼Â÷, ¿¬·É, üÁß µîÀÌ ÀÖ°í, ¾à¹°ÂÊ ÀÎÀڷμ´Â Åõ¿©¹æ¹ý, Åõ¿©·®, º´¿ëµÇ°í ÀÖ´Â ´Ù¸¥ ¾à¹° µîÀÌ ÀÖ´Ù. 2. ¾àÀÇ Àç·á°¡ µÇ´Â ¹°Áú. 3. ¿©·¯ °¡Áö ¾àÀ縦 ¼¯¾î Á¶Á¦ÇÑ ¾à. |
||
| ¿µ¹® | drug resistance | ÇÑ±Û | ¾à¹°³»¼º |
|---|---|---|---|
| ¼³¸í | 1. ÈÇпä¹ýÁ¦³ª Ç×»ý¹°ÁúÀÇ ¾î¶² ÀÏÁ¤ ³óµµ·Î ¼¼±ÕÀ» Á×À̰ųª Áõ½ÄÀúÇØ¸¦ ¹Þ´Â °ÍÀ» ÀÌ ÈÇпä¹ýÁ¦³ª Ç×»ý¹°Áú¿¡ °¨¼ö¼ºÀÌ ÀÖ´Ù°í Çϴµ¥, ÀÌ °¨¼ö¼ºÀÌ ¾ø°Ô µÈ »ýŸ¦ ÀúÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. µû¶ó¼ º¯À̹̻ý¹°ÀÇ ¾àÁ¦¿¡ ´ëÇÑ ÀÚÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. 2. ÀǾàǰÀ» °è¼Ó º¹¿ëÇϸé Á¡Â÷ Áõ·®ÇÏÁö ¾ÊÀ¸¸é È¿·ÂÀÌ ³ªÅ¸³ªÁö ¾Ê´Â ¼ºÁú. ÀÌ·¯ÇÑ ¶§¸¦ ¾àÁ¦³»¼ºÀÌ »ý°å´Ù°í ÇÑ´Ù. ¸ðµç ¹Ì»ý¹°Àº °¨¼ö¼ºÀ» °¡Áö´Â ¾à¹°¿¡ ÀÇÇÏ¿© »ç¸êµÇÁö¸¸, ¼Ò¼öÀÇ °ÍÀº »ì¾Æ³²¾Æ ±×°ÍÀÌ ÁøÈµÊÀ¸·Î½á »ç¸êÇÏÁö ¾Ê´Â ¼ö°¡ ÀÖ´Ù. ¶Ç, ÃÖÃÊ¿¡´Â °¨¼ö¼ºÀ» °¡Áö°í ÀÖ´ø ±ÕÀÌ Â÷Â÷ ³»¼º±ÕÀ¸·Î µÇ±âµµ ÇÑ´Ù. ¸¹Àº º´¿ø±ÕÀº °¨¼ö¼ºÀÌ ÀÖ´Â ÀǾàǰ¿¡ ´ëÇÏ¿© ³»¼ºÀÌ »ý±ä´Ù. °¡Àå °íµµÀÇ ³»¼º±ÕÀÌ »ý±â±â ½¬¿î °ÍÀº ½ºÆ®·¾Å丶À̽ÅÀε¥ °áÇÙ±Õ°ú ±×¶÷À½¼º±Õ¿¡ ´ëÇÏ¿© ½±°Ô ³»¼ºÀÌ »ý±ä´Ù. Æä´Ï½Ç¸°À̳ª Åׯ®¶ó½ÃŬ¸°(¾ÆÅ©·Î¸¶À̽Å) µîÀÇ Ç×»ý¹°Áúµµ ³»¼ºÀÌ »ý±â±â ½¬¿ì¹Ç·Î, »ç¿ëÇÒ ¶§´Â ÀûÀÀÀ» Àß È®ÀÎÇÏ¿© Çʿ䷮À» Á¤ÇÏ°í ¿¬¿ëÀ» ÇÇÇÑ´Ù. °°Àº È¿°ú°¡ ÀÖ´Â ´Ù¸¥ Á¾·ùÀÇ ¾àÁ¦¸¦ ¼Ò·®¾¿ 2, 3Á¾ º´¿ëÇÏ¸é ³»¼ºÀÇ ¹ß»ýÀÌ Å©°Ô ¾ïÁ¦µÈ´Ù´Â °ÍÀÌ ¾Ë·ÁÁ® ÀÖ´Ù. °áÇÙ¾àÀ¸·Î¼ ½ºÆ®·¾Å丶À̽Űú ÆÄ½º, ¶Ç´Â À̼ҴϾÆÁöµå¸¦ º´¿ëÇÏ´Â °Í µîÀÌ ±× ¿¹ÀÌ´Ù. |
||
| PERLA | pupils equal, react to light and accommodation |
|---|---|
| ADE | acute disseminated encephalitis; adverse drug event; antibody-dependent enhancement; apparent digest... |
| ADR | activation, depression, repetition [in bone remodeling]; adrenodoxin reductase; Adriamycin; adverse ... |
| SADR | suspected adverse drug reaction |
| DA | dark adaptation; dark agouti [rat]; daunomycin; degenerative arthritis; delayed action; Dental Assis... |
| ADE | Adverse Drug Event |
|---|---|
| ADR | Adverse Drug Reaction |
| RRE | REV response element |
| REV | Reticuloendotheliosis virus |
| REV-T | Reticuloendotheliosis virus strain T |
| adverse drug reaction reporting systems | Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions. (12 Dec 1998) |
|---|---|
| react | 1. To return an impulse or impression; to resist the action of another body by an opposite force; as, every body reacts on the body that impels it from its natural state. 2. To act upon each other; to exercise a reciprocal or a reverse effect, as two or more chemical agents; to act in opposition. Source: Websters Dictionary (01 Mar 1998) |
| gene products, rev | Trans-acting nuclear proteins whose functional expression are required for HIV viral replication. Specifically, the rev gene products are required for processing and translation of the HIV gag and env mRNAs, and thus rev regulates the expression of the viral structural proteins. Rev can also regulate viral regulatory proteins. A cis-acting antirepression sequence (car) in env, also known as the rev-responsive element (rre), is responsive to the rev gene product. Rev is short for regulator of virion. (12 Dec 1998) |
| genes, rev | DNA sequences that form the coding region for a protein that regulates the expression of the viral structural and regulatory proteins in human immunodeficiency virus (HIV). Rev is short for regulator of virion. (12 Dec 1998) |
| rev | <molecular biology> A regulatory protein produced by HIV within infected cells. Rev helps transport HIV RNA sequences (messenger RNA) out from the nucleus into the cells cytoplasm, where it directs construction of proteins for new virus particles. (11 Jan 1998) |
| drug-drug interaction | The effects that occur when two or more drugs are used together. Such effects include changes of absorption in the digestive tract, changes in rate of the drugs' breakdown in the liver, new or enhanced side effects and changes in the drugs' activity. (09 Oct 1997) |
| adverse | Harmful. (18 Nov 1997) |
| adverse effect | This is an abnormal or harmful effect to an organism caused by exposure to a chemical. It is indicated by some result such as death, a change in food or water consumption, altered body and organ weights, altered enzyme levels, or visible illness. An effect may be classed as adverse if it causes functional or anatomical damage, causes irreversible change in the homeostasis of the organism, or increases the susceptibility of the organism to other chemical or biological stress. A non-adverse effect will usually be reversed when the organism is no longer being exposed to the chemical. (09 Oct 1997) |
| adverse event | A toxic reaction to a medical therapy. (09 Oct 1997) |
| adverse reaction | Any undesirable or unwanted consequence of a preventive, diagnostic, or therapeutic procedure or regimen. (05 Mar 2000) |
| no-observed-adverse-effect level | The highest dosage administered that does not produce toxic effects. The noael will depend on how closely dosages are spaced (lowest-observed-adverse-effect level and no-observed-effect level) and the number of animals examined. The ultimate objective is usually to determine not the "safe" dosage in laboratory animals but the "safe" dosage for humans. Therefore, the extrapolation most often required of toxicologists is from high-dosage studies in laboratory animals to low doses in humans. (casarett and doull's toxicology: the basic science of poisons, 4th ed) (12 Dec 1998) |
| event, adverse | In pharmacology, an adverse event is any unexpected or dangerous reaction to a drug. (12 Dec 1998) |
| abnormalities, drug-induced | Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment. (12 Dec 1998) |
| activity, drug | A measure of the physiological response a drug produces in the body. A less active drug produces less response (and visa versa). (12 Dec 1998) |
| addictive drug | Any drug that creates a certain degree of euphoria and has a strong potential for addiction. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|